ForPatients

by Roche

Asthma

A study to find out if a new medicine – MTPS9579A – works in people with asthma

A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of MTPS9579A in Patients With Asthma Requiring Inhaled Corticosteroids and a Second Controller

Trial Status Trial Runs In Trial Identifier

Completed 5 Countries NCT04092582 2019-000795-41

GB41149

The source of the below information is the publicly available website ClinicalTrials.gov. It has been summarised and edited into simpler language.

Trial Summary:

This clinical trial was done to study a new medicine called, MTPS9579A, for the treatment of asthma. This study investigated whether MTPS9579A was effective for controlling asthma in people who used inhaled corticosteroids (ICS) and another medicine – a second controller for the asthma. This was a Phase 2a, multicenter, randomized, placebocontrolled, double-blind study, conducted at 26 study centers in 5 countries.

Genentech, Inc. (A part of F. Hoffmann-La Roche Ltd., Switzerland) Sponsor		Phase 2a Phase		
NCT04092582 2019-000795-41 GE Trial Identifiers	341149			
Eligibility Criteria:				
Gender All	Age >=18 Years & <= 75 Years		Healthy Volunteers	